Congenia

Congenia is an Italian biotechnology company dedicated to the discovery and development of first-in-class small molecule drugs targeting the biology of aging. The company was founded as a spin-off from the IFOM-IEO Campus in Milan, based on the pioneering research of Professor Pier Giuseppe Pelicci regarding the p66Shc protein. This protein is a key regulator of oxidative stress and mitochondrial function, making it a significant target for treating age-related pathologies. Congenia's primary focus is on developing inhibitors to treat conditions such as ischemia-reperfusion injury, cardiovascular diseases, and diabetic complications. As a subsidiary of the Genextra Group, the company leverages a deep understanding of molecular longevity pathways to create innovative therapeutic interventions.